Phenelzine

Generic Name: Phenelzine

Brand Names: Nardil

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₂N_₂

CAS Number: 51-71-8

Unique Ingredient Identifier: O408N561GF

Background: Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

Indication: Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.
...

Associated Conditions: Exogenous depression, Neurotic depression, Atypical Depressive disorder

Associated Therapies: -

Clinical Trials

Precision Care for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder
Depression
Depressive Disorder, Major

Interventions: Other: Care as usual (CAU) plan
Behavioral: Complicated Grief Treatment (CGT)
Drug: Pramipexole
Drug: Methylphenidate
Behavioral: Mindfulness-based Stress Sensitivity Therapy (MBSST)
Drug: Phenelzine

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 150

Registration Number: NCT06580041

Locations: 🇺🇸
Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco, San Francisco, California, United States

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: Phenelzine
Drug: Rasigiline
Drug: Ozanimod

First Posted Date: 2021-07-27

Last Posted Date: 2023-08-31

Lead Sponsor: Celgene

Target Recruit Count: 128

Registration Number: NCT04978298

Locations: 🇺🇸
Local Institution - 001, Anaheim, California, United States

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Phenelzine
Drug: Tyramine
Drug: Phenelzine placebo
Drug: ozanimod
Drug: ozanimod placebo

First Posted Date: 2018-10-03

Last Posted Date: 2019-07-19

Lead Sponsor: Celgene

Target Recruit Count: 92

Registration Number: NCT03694119

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy